Antonios Papanicolau-Sengos, M.D.

Antonios Papanicolau-Sengos, M.D.
Assistant Research Physician
Laboratory of Pathology

Dr. Papanicolau-Sengos is a molecular pathologist. He is interested in targeted oncotherapeutics, the molecular classification of neoplasms, and machine learning applications in molecular pathology

Areas of Expertise

1) neoplasm molecular genomics, 2) epigenetic oncology

Contact Info

Antonios Papanicolau-Sengos, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 3S235B
Bethesda, MD 20892
Ph: 301-480-5010
antonios.papanicolau-sengos@nih.gov

I am interested in new analytical technologies in the context of molecular pathology. An example is the application of machine learning techniques on large-scale DNA methylation studies. The combination of these technologies has already proved excellent in helping neuropathologists classify central nervous system (CNS) neoplasms. Another interest of mine is the molecular characterization of rare familial neoplasms which are not currently well-represented in medical literature.

NIH Scientific Focus Areas:
Cancer Biology, Cell Biology, Clinical Research, Computational Biology, Immunology
View Dr. Papanicolau-Sengos' PubMed Summary.

Selected Recent Publications

  1. Identification of targets for prostate cancer immunotherapy.
    Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C.
    Prostate. 79(5): 498-505, 2019. [ Journal Article ]
  2. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
    Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz- Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C.
    J Immunother Cancer. 7(1): 18, 30678715. [ Journal Article ]
  3. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
    Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.
    J Immunother Cancer. 7(1): 27, 2019. [ Journal Article ]

Dr. Papanicolau-Sengos received his medical degree from Georgetown School of Medicine and has completed a pathology residency (AP/CP) at the University of California San Diego, a general surgical pathology fellowship at the University of Washington, and a molecular pathology fellowship at ARUP laboratories. Previously, Dr. Papanicolau-Sengos has held positions at the molecular pathology laboratory of Roswell Park Comprehensive Cancer Center and its spin-off company OmniSeq Inc.